Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. is currently overvalued at $17.22 due to significant financial challenges, including a price-to-book ratio of 1.57, an EV to EBITDA of -1.95, and a return on equity of -27.71%, all while underperforming compared to its peers and the S&P 500.

As of April 21, 2025, the technical trend is mildly bearish due to conflicting signals from daily moving averages and weekly MACD, despite a bullish monthly RSI, with the stock underperforming relative to the S&P 500.

As of March 2022, the management team of Neoleukin Therapeutics, Inc. includes Mr. Todd Simpson (Independent Chairman), Dr. Jonathan Drachman (CEO), and several directors: Mr. Martin Babler, Ms. Erin Lavelle, Ms. M. Cantey Boyd, Dr. Sarah Noonberg, and Dr. Lewis Williams. This team combines executive leadership with independent directors for effective governance.

Neoleukin Therapeutics, Inc. is a biopharmaceutical company that develops computationally-designed protein therapeutics for immuno-oncology, inflammation, and autoimmunity. It has a market cap of $386.45 million and reported a net profit loss of $23 million as of March 2025.

As of Jun 18, Neoleukin Therapeutics, Inc. has a market capitalization of 386.45 million and reported net sales of 0.93 million with a net profit of -80.87 million over the latest four quarters. The company has shareholder's funds of 310.38 million and total assets of 336.44 million as of Dec 24.